Evidence map›Paper›PMID 37066690›Full record

Trial reportInternational psychogeriatrics2023

Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).

Krista L Lanctôt, Clara Chen, Ethan Mah, Alex Kiss, Abby Li, Dave Shade, Roberta W Scherer, Danielle Vieira, Hamadou Coulibaly, Paul B Rosenberg and 10 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International psychogeriatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02346201 (Apathy in Dementia Methylphenidate Trial 2), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02346201 phase3completednot on this map

Apathy in Dementia Methylphenidate Trial 2

TypeinterventionalSponsorJohns Hopkins Bloomberg School of Public HealthRan2016 to 2020Enrolled200ConditionsApathy, Alzheimer's DiseaseArmsMethylphenidate, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Krista L LanctôtSunnybrook Research Institute, Toronto, ON, Canada.ORCID 0000-0001-7024-6637
Clara ChenFaculty of Health Sciences, Western University, London, ON, Canada.
Ethan MahSunnybrook Research Institute, Toronto, ON, Canada.
Alex KissSunnybrook Research Institute, Toronto, ON, Canada.
Abby LiSunnybrook Research Institute, Toronto, ON, Canada.
Dave ShadeJohns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
Roberta W SchererJohns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
Danielle VieiraSunnybrook Research Institute, Toronto, ON, Canada.
Hamadou CoulibalyJohns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
Paul B RosenbergJohns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-1106-4299
Alan J LernerUniversity Hospital - Case Western Reserve University, Cleveland, OH, USA.
Prasad R PadalaUniversity of Arkansas for Medical Science, Central Arkansas Veterans Healthcare System, Little Rock, AR, USA.ORCID 0000-0003-1921-9806
Olga Brawman-MintzerMedical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA.
Christopher H van DyckYale University, New Haven, CT, USA.
Anton P PorsteinssonUniversity of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Suzanne CraftWake Forest University School of Medicine, Winston-Salem, NC, USA.
Allan LeveyEmory University, Atlanta, GA, USA.
William J BurkeBanner Alzheimer's Institute, Phoenix, AZ, USA.
Jacobo MintzerMedical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA.
Nathan HerrmannSunnybrook Research Institute, Toronto, ON, Canada.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER, CHRISTOPHER H VAN DYCK · 2020 to 2026
$30.2M
Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3M
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)R01AG046543 · NIA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HERRMANN, NATHAN, LANCTOT, KRISTA L. · 2014 to 2018
$8.1M
Using connectomics to characterize risk for Alzheimer's DiseaseR01AG055132 · NIA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI JOSEPH, JANE E, MINTZER, JACOBO · 2017 to 2021
$3.7M
NCATS NIH HHS UL1 TR001863NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG072947NIA NIH HHS R01 AG046543NIA NIH HHS R01 AG055132RRD VA I01 RX002638
6 · The paper itself

Abstract

backgroundThis paper used data from the Apathy in Dementia Methylphenidate Trial 2 (NCT02346201) to conduct a planned cost consequence analysis to investigate whether treatment of apathy with methylphenidate is economically attractive.

methodsA total of 167 patients with clinically significant apathy randomized to either methylphenidate or placebo were included. The Resource Utilization in Dementia Lite instrument assessed resource utilization for the past 30 days and the EuroQol five dimension five level questionnaire assessed health utility at baseline, 3 months, and 6 months. Resources were converted to costs using standard sources and reported in 2021 USD. A repeated measures analysis of variance compared change in costs and utility over time between the treatment and placebo groups. A binary logistic regression was used to assess cost predictors.

resultsCosts were not significantly different between groups whether the cost of methylphenidate was excluded ( DISCUSSION: Results from this study indicated that there was no evidence for a difference in resource utilization costs between methylphenidate and placebo treatment. However, utility improved significantly over the 6-month follow-up period. These results can aid in decision-making to improve quality of life in patients with Alzheimer's disease while considering the burden on the healthcare system.

Indexed as

Alzheimer DiseaseApathyCentral Nervous System StimulantsMethylphenidateHumansQuality of LifeCentral Nervous System StimulantsMethylphenidateAlzheimer’s disease (AD)apathydementiahealth economics

Identifiers

PMID37066690
PMCPMC10579450

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.